Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Gains from Sales and Divestitures: 2015-2018

  • Spyre Therapeutics' Gains from Sales and Divestitures was N/A to $26,444 in Q4 2018 from the same period last year, while for Dec 2018 it was $26,444, marking a year-over-year change of. This contributed to the annual value of $26,444 for FY2018, which is N/A change from last year.
  • Latest data reveals that Spyre Therapeutics reported Gains from Sales and Divestitures of $26,444 as of Q4 2018, which was down 18.85% from $32,588 recorded in Q4 2015.
  • In the past 5 years, Spyre Therapeutics' Gains from Sales and Divestitures ranged from a high of $32,588 in Q4 2015 and a low of $26,444 during Q4 2018.
  • Over the past 1 years, Spyre Therapeutics' median Gains from Sales and Divestitures value was $26,444 (recorded in 2018), while the average stood at $26,444.